NEW YORK, May 22, 2026, 06:04 EDT
HeartBeam Inc. traded near $1 in light premarket action Friday, with shares at $0.94 before the open, up 2.03%. The stock closed at $0.92 on Thursday. Investors are weighing some early sales gains against questions about the company’s funding. Market cap showed about $51 million and the 52-week range is $0.54 to $4.00, according to .
BEAT is moving in premarket, where trading volume is usually thin. Nasdaq lists regular market hours as 9:30 a.m. to 4 p.m. ET, with premarket running 4 a.m. to 9:30 a.m. U.S. markets are closed on Monday, May 25 for Memorial Day, according to the 2026 stock-market calendar.
HeartBeam shares moved Friday without any new update on its investor-relations page since first-quarter results posted May 13. The company markets a portable electrocardiogram system, saying its device and software generate a 12-lead ECG for clinicians to use. HeartBeam says the cleared output is meant for manual review of certain non-life-threatening arrhythmias and does not do cardiac analysis.
HeartBeam is working to move its clearance into actual sales. On the call, CEO Robert Eno said ClearCardio and Atelier Health were onboard, so now it has early commercial sites in New York, Dallas, South Florida and Southern California. Chief Financial Officer Timothy Cruickshank said the first half was “not a revenue story.” Chief Commercial Officer Bryan Humbarger said clinician feedback “exceeded my expectations.” Investing
HeartBeam’s May 13 update said the first patients have enrolled in ALIGN-ACS, its heart-attack detection pilot trial, and the company has also started a pilot of an on-demand 12-lead ECG patch targeting ischemia. Eno said HeartBeam had “made significant progress executing” and is staying focused on “expanding our commercial footprint.” Cloudfront
HeartBeam is still under pressure. The company posted a first-quarter net loss of $4.7 million, better than the $5.5 million loss from the same period last year. Operating cash use was $3.6 million, a 19% decline year over year. HeartBeam held $2.0 million in cash at the end of March, and pulled in $11.5 million in gross proceeds from its April stock offering, after triggering the full over-allotment.
But the downside is clear. HeartBeam’s latest 10-Q reports it has posted losses and used up cash every year since it started. The company doesn’t expect meaningful commercial revenue in 2026 and says its current cash won’t last another 12 months. That’s triggered “substantial doubt” about continuing as a going concern—meaning HeartBeam could need fresh financing. More stock sales risk diluting current holders, since the shares still trade under $1. Equisolve
iRhythm Technologies says its Zio ECG monitors have collected data from over 12 million patients, helping doctors spot arrhythmias. HeartBeam is taking a different route, aiming to give clinicians 12-lead-style data outside the clinic. That could be a plus, but it means HeartBeam has to convince doctors to shift their workflow, not just use a new monitor.
At this stage, investors are watching patient uptake, contract terms and cash more than press releases. Shares look set to move on early commercial progress—like how quickly first sites ramp up, or if pilot programs deliver numbers that could bolster bigger regulatory plans. How the company funds this work, and if it can do it without hitting up shareholders, will be key.
